In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Next Big Thing In Gene Therapy Might Not Be Gene Therapy

Executive Summary

Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.

You may also be interested in...



Gene Therapy Situation Gets More Awkward With Another Death In Astellas XLMTM Study

An expert pointed out that XLMTM patients are already at high risk, but if linked to therapy toxicity, the death could doom the ASPIRO trial.

Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology

Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy.

Shape Therapeutics’ Big Financing Shows Growing Interest In Novel Capsids

Several companies have recently raised large amounts of money from venture capital as well as potentially through partnerships for next-generation capsid technology.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

IV124913

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel